Skip to Main content Skip to Navigation
Journal articles

Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells.

Abstract : Allergic asthma is an inflammatory disease of the airways, resulting from an inappropriate immune response to inhaled allergens, which involves multiple inflammatory cells and mediators that contribute to airway hyper-responsiveness. Omalizumab is a monoclonal antibody, specifically directed to the C-Epsilon3 domain of immunoglobulin E (IgE), indicated as an additional therapy in severe allergic asthma [1]. Impaired function of regulatory T cells (Treg) is incriminated in the aberrant asthma inflammatory response [2].
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-01404099
Contributor : Flore Amat <>
Submitted on : Monday, November 28, 2016 - 1:03:54 PM
Last modification on : Wednesday, August 19, 2020 - 11:17:20 AM

Links full text

Identifiers

Citation

Flore Amat, Pauline Tallon, Anne Perrine Foray, Bénédicte Michaud, Nathalie Lambert, et al.. Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells.. Clinical and Experimental Allergy, Wiley, 2016, Epub ahead of print. ⟨10.1111/cea.12839⟩. ⟨inserm-01404099⟩

Share

Metrics

Record views

376